Jodi L. Layton

Ophthalmology
164 Summit Ave
Providence, RI 02906

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Prediction of Resistance to 177Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers.

Prediction of Resistance to 177Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: June 13, 2023

Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamide.

Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamide.

Journal: The Prostate
Published: January 25, 2023

Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer.

Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer.

Journal: The Prostate
Published: October 17, 2022

Clinical and Genetic Analysis of Metastatic Prostate Cancer to the Central Nervous System: A Single-Institution Retrospective Experience.

Clinical and Genetic Analysis of Metastatic Prostate Cancer to the Central Nervous System: A Single-Institution Retrospective Experience.

Journal: Clinical genitourinary cancer
Published: September 01, 2022

Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus Avelumab.

Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus Avelumab.

Journal: The oncologist
Published: June 02, 2022

Continuous IV Infusion of 5-Flourouracil in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer.

Continuous IV Infusion of 5-Flourouracil in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer.

Journal: Clinical genitourinary cancer
Published: May 20, 2022

Embracing the Practical Aspects of Theranostics With Prostate-Specific Membrane Antigen-Targeted Lutetium-177.

Embracing the Practical Aspects of Theranostics With Prostate-Specific Membrane Antigen-Targeted Lutetium-177.

Journal: Practical radiation oncology
Published: January 04, 2022

Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.

Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.

Journal: The Prostate
Published: January 26, 2021

Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.

Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.

Journal: The Prostate
Published: January 09, 2021

Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.

Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.

Journal: Journal for immunotherapy of cancer
Published: July 19, 2020

Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort.

Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort.

Journal: Frontiers in oncology
Published: July 08, 2020

Long-Term Disease Control Using Taxane/Platinum-Based Chemotherapy in CDK12-Mutated Advanced Prostate Cancer.

Long-Term Disease Control Using Taxane/Platinum-Based Chemotherapy in CDK12-Mutated Advanced Prostate Cancer.

Journal: The oncologist
Published: March 31, 2020
Showing 1-12 of 19

Last Updated: 09/26/2026